The latest study conducted by Indian Council of Medical Research (ICMR) shows that antibodies generated by Omicron, a COVID-19 strain, are not only effective against it but also other variants of concern (VOCs) including Delta.
“The individuals infected with Omicron have significant immune response which could neutralize not only the Omicron but also the other VOCs including most prevalent Delta variant,” a study by ICMR has revealed. “This suggests that the immune response induced by the Omicron could effectively neutralize the Delta variant making the re-infection with Delta less likely, thereby displacing the Delta as dominant strain. This emphasizes the need for the Omicron specific vaccine strategy,” it further said.
In this study, the ICMR has analysed the IgG and neutralizing antibodies (NAbs) against B.1, Alpha, Beta, Delta and Omicron variants with the sera of individuals infected with the Omicron variant (B.1.1529 and BA.1) as currently India is facing the third wave of the COVID-19 pandemic.
ICMR has said that within a short span of time, the variant has shown high transmissibility and capability of evading the immune response generated against natural infection and vaccination. The immune escape potential of Omicron is a serious concern and further needs to be explored.
The study, where antibodies response was assessed in those who are infected by Omicron, is pre-print. And not peer reviewed.
Although COVID-19 cases are showing a downward trend in the big cities, the ICU admissions and deaths are being driven by patients with comorbidities, people who are immunocompromised, and the aged.
Dr Suranjit Chatterjee, senior consultant, Internal Medicine, Apollo Hospital said, “It is comorbidity which is causing ICU admissions. Even before COVID-19, people with comorbidities, extreme age require ICU admission quite a few times with any of the infections. Rather than Omicron causing ICU admissions, it is the comorbidities, because superimposed infection which happens to be Omicron is causing the ICU admission.”
“When numbers are high, deaths actually follow them. Cases have started coming down in metropolitan cities but people actually die a couple of weeks down the line. They become more serious and come up with more complications and start dying. Thus, the discrepancy occurs that when peak has already been seen and cases are reducing each day (especially in Mumbai and Delhi) the deaths have slightly risen and this what happens epidemiologically,” Dr Chatterjee said.
MARKET NOD
The regular market approval from Drugs Controller General of India (DCGI) to COVID-19 vaccine Covishield and Covaxin is expected soon, but only after price is fixed, official sources said on Wednesday.
Recently, the National Pharmaceutical Pricing Authority (NPPA), DCGI, Drug regulators and senior officials of the Union Health Ministry conducted a meeting regarding fixing the prices of Covishield and Covaxin, but no final decision has been taken yet.
It is expected that the price of a vaccine will be fixed below Rs 275 per dose and additional service charges of 150 to make both the vaccines affordable for all.
